![[CCO] Certification Coaching Organization LLC](https://staging.cco.us/wp-content/uploads/2015/05/CCO-Logo-2015-d3-500px.png "[CCO] Certification Coaching Organization LLC"){kind=logo}
🔍 Definition
Parkinson's disease (PD) is a chronic, progressive neurodegenerative disorder characterized by the selective loss of dopaminergic neurons in the substantia nigra pars compacta and the accumulation of misfolded alpha-synuclein protein aggregates (Lewy bodies) in surviving neurons. The pathological hallmark is dopamine depletion in the nigrostriatal pathway, producing the cardinal motor features of the disease. According to the Parkinson's Foundation, approximately 1 million people in the United States currently live with Parkinson's disease, with nearly 90,000 new diagnoses each year.
For coding purposes, a critical distinction exists among three categories:
- Idiopathic (primary) Parkinson's disease — coded to category G20.x. This is the most common form, representing approximately 85–90% of all parkinsonism cases, and arises from unknown etiology with characteristic Lewy body pathology.
- Secondary parkinsonism — coded to category G21.x. These are parkinsonian syndromes caused by identifiable external factors including drugs, toxins, vascular disease, or infection.
- Parkinson-plus syndromes (degenerative basal ganglia diseases) — coded to category G23.x. These atypical parkinsonisms include progressive supranuclear palsy (PSP), multiple system atrophy (MSA), and others. They differ clinically and have different RAF/HCC implications.
The terms "Parkinson's disease," "parkinsonism," and "Parkinson's syndrome" are not interchangeable for coding purposes. Effective April 1, 2026, the ICD-10-CM Alphabetic Index was updated so that documented "Parkinson's disease" directs coders to G20.A1 (not G20.C as before the October 2023 expansion). "Parkinson's syndrome or tremor" continues to route to G21 (parkinsonism). Verify precise provider language before code assignment.
🗂️ Alternative Terminology
| Formal / Clinical Name | Colloquial / Lay Terms / Synonyms |
|---|---|
| Parkinson's disease (idiopathic) | Parkinson's, PD, shaking palsy, paralysis agitans |
| Primary parkinsonism | Idiopathic Parkinson's, true Parkinson's |
| Secondary parkinsonism | Drug-induced parkinsonism, vascular parkinsonism, toxic parkinsonism |
| Drug-induced parkinsonism | Neuroleptic-induced parkinsonism, medication-induced parkinsonism |
| Progressive supranuclear palsy (PSP) | Steele-Richardson-Olszewski syndrome |
| Multiple system atrophy (MSA) | Shy-Drager syndrome (historical), MSA-P (parkinsonian variant), MSA-C (cerebellar variant), olivopontocerebellar atrophy |
| Parkinson's disease with dementia (PDD) | Parkinsonian dementia, dementia in Parkinson's |
| Dementia with Lewy bodies (DLB) | Lewy body dementia, diffuse Lewy body disease |
| Wearing-off phenomenon | End-of-dose deterioration, "off" episodes, motor fluctuations |
| Levodopa-induced dyskinesia (LID) | Peak-dose dyskinesia, choreiform movements in PD |
| Hoehn and Yahr staging | H&Y scale, PD staging scale |
| Deep brain stimulation (DBS) | Brain pacemaker, DBS implant, neurostimulator therapy |
🩺 Signs & Symptoms
Cardinal Motor Features (TRAP Mnemonic)
- Tremor — Resting tremor (pill-rolling), 4–6 Hz frequency; asymmetric onset; suppressed by voluntary movement
- Rigidity — Cogwheel or lead-pipe resistance to passive movement; may present as shoulder pain
- Akinesia/Bradykinesia — Slowness of initiation and execution of movement; micrographia; hypomimia (masked face); hypophonia
- Postural instability — Impaired balance and righting reflexes; hallmark of later disease (Hoehn-Yahr stage 3+)
Motor Complications (Critical for FY2026 Code Selection)
- Motor fluctuations ("off" episodes) — Wearing-off at end of dose, unpredictable "on/off" switching, early morning akinesia; affects code selection for G20.A2 vs. G20.B2
- Levodopa-induced dyskinesia (LID) — Involuntary choreiform or dystonic movements during "on" periods; key clinical indicator for G20.B1/G20.B2 assignment
- Freezing of gait (FOG) — Sudden inability to initiate or continue walking; major fall risk
Non-Motor Features
- Autonomic dysfunction: Orthostatic hypotension, constipation (K59.00), urinary dysfunction including urinary incontinence (N39.41), sialorrhea, seborrhea
- Cognitive/neuropsychiatric: Mild cognitive impairment, Parkinson's disease dementia (PDD) — coded with F02.x as manifestation; depression (F32.x/F33.x); anxiety; psychosis (hallucinations, delusions)
- Sleep disorders: REM sleep behavior disorder (RBD) — G47.52 (may precede motor onset by years); insomnia; excessive daytime sleepiness
- Sensory: Anosmia (often pre-motor symptom), pain, restless legs
- Dysphagia: R13.1x — aspiration risk; associated with aspiration pneumonia (J69.0), a major comorbidity requiring attention during inpatient stays
- Falls: W19.xxXA — high frequency, high injury risk; critical to document fall history and Hoehn-Yahr stage
Hoehn and Yahr Staging System
| Stage | Clinical Description | Functional Impact |
|---|---|---|
| Stage 1 | Unilateral disease only; minimal or no functional impairment | Independent |
| Stage 1.5 | Unilateral + axial involvement | Minimal limitation |
| Stage 2 | Bilateral disease, no postural instability | Some limitations, fully independent |
| Stage 2.5 | Bilateral disease, recovery from pull test | Functional with some difficulties |
| Stage 3 | Mild to moderate bilateral disease; postural instability; physically independent | Significant gait/balance issues |
| Stage 4 | Severe disability; still walks, severely limited | Requires assistance; cannot live alone |
| Stage 5 | Wheelchair-bound or bedridden; requires constant care | Total dependence |
Hoehn-Yahr stage is not directly encoded in ICD-10-CM. However, stage documentation drives important code selection decisions: stages 3–5 imply postural instability/gait difficulty (PIGD) variant, which may support W19 fall coding and influence UPDRS documentation, DBS candidacy, and CDI query triggers. Always document the scale score in queries and flag it in the record.
🧭 Differential Diagnosis
| Condition | Key Distinguishing Features | ICD-10-CM Code |
|---|---|---|
| Idiopathic Parkinson's disease (G20.x) | Asymmetric onset, resting tremor, levodopa responsiveness, Lewy body pathology, gradual progression | G20.A1–G20.B2 (see FY2026 codes below) |
| Drug-induced parkinsonism (G21.11, G21.19) | Symmetric, history of antipsychotic/metoclopramide use, resolves after drug cessation, lacks resting tremor typically | G21.11 (neuroleptic), G21.19 (other) |
| Progressive supranuclear palsy (PSP) (G23.1) | Vertical gaze palsy, falls backward, axial rigidity, early postural instability, poor levodopa response | G23.1 |
| Multiple system atrophy (MSA) (G23.2, G23.3) | Autonomic failure (orthostatic hypotension), cerebellar signs (MSA-C), parkinsonian features (MSA-P), poor levodopa response | G23.2 (MSA-C), G23.3 (MSA-P) |
| Dementia with Lewy bodies (DLB) (G31.83) | Visual hallucinations precede motor features; cognitive fluctuations; REM sleep behavior disorder; sensitivity to antipsychotics; dementia onset within 1 year of motor symptoms | G31.83 |
| Vascular parkinsonism (G21.4) | Lower body predominant ("lower-half parkinsonism"), history of cerebrovascular disease, step-wise progression, white matter lesions on MRI | G21.4 |
| Essential tremor (G25.0) | Action/postural tremor (not resting), family history common, head tremor, voice tremor, no bradykinesia or rigidity, alcohol-responsive | G25.0 |
| Corticobasal syndrome (CBS) | Apraxia, cortical sensory loss, alien limb phenomenon, unilateral dystonia, poor levodopa response | G23.8 |
| Normal pressure hydrocephalus (NPH) | Classic triad: gait instability, urinary incontinence, dementia; wide-based shuffling gait; MRI shows ventricular enlargement | G91.2 |
| Postencephalitic parkinsonism (G21.3) | History of encephalitis, may follow viral illness, oculogyric crises, dystonia, may have prolonged course | G21.3 |
📋 Clinical Indicators for Coders/CDI
| Clinical Indicator | Coding/Documentation Impact | Action Required |
|---|---|---|
| Tremor-dominant vs. PIGD phenotype | Tremor-dominant = better prognosis; PIGD = higher fall risk, faster cognitive decline — both affect DRG and care intensity | Query for phenotype if not documented |
| Presence of dyskinesia (G20.B1/G20.B2) | Selects B-series subcodes vs. A-series; indicates advanced disease and levodopa complications | Document per each encounter — dyskinesia may fluctuate |
| Motor fluctuations / "off" episodes (G20.A2/G20.B2) | Selects "with fluctuations" subcodes; affects medication management complexity | Query if not explicitly stated; review medication timing notes |
| Dementia with Parkinson's (F02.x) | Requires etiology/manifestation coding: G20.x sequenced first, F02.80/F02.81x second; affects HCC for cognitive complexity | Document severity and behavioral disturbance status |
| Behavioral disturbance with dementia (F02.81x) | Fifth-character specificity: .810 (without psychotic), .811 (with psychotic features), .812 (with agitation), .813 (with apathy), .818 (other), .819 (unspecified) | Query for specific behavioral manifestation |
| Hoehn-Yahr stage documented | Stage 3–5 supports medical necessity for PT/OT, DBS evaluation, home health, SNF | Ensure stage appears in assessment/plan |
| Dysphagia (R13.1x) present | Additional code required; drives speech therapy (92507) and aspiration precautions; increases aspiration pneumonia risk (J69.0) | Specify severity: R13.10 (unspecified), R13.11 (oral phase), R13.12 (oropharyngeal), R13.13 (pharyngeal), R13.14 (pharyngoesophageal) |
| DBS implant status | Z95.89 (presence of other cardiac and vascular implants) is sometimes used; more precisely Z86.39 or Z45.49 for management — verify in tabular; primary Dx is the underlying condition (G20.x) | Code underlying PD as primary; Z45.49 for device management encounters |
| Falls (W19.xxXA) | Secondary code; documents injury risk; influences MDM complexity and care planning; required for present on admission (POA) tracking | Use for all encounters documenting fall(s); code injury if applicable |
| Idiopathic (G20.x) vs. secondary (G21.x) vs. Parkinson-plus (G23.x) | Different HCC weights; different prognosis; DBS coverage requires idiopathic PD specifically | Ensure clear documentation of etiology; query if unclear |
When the record documents parkinsonism, tremor, or bradykinesia without specifying idiopathic vs. secondary vs. Parkinson-plus, or when the chart mentions only "parkinsonism" — consider a clarification query. The April 2026 ICD-10-CM index update makes this distinction critical: "Parkinson's disease" routes to G20.A1 while "parkinsonism" routes to the G21 category. Per UASI Solutions, provider terminology must match the intended diagnosis.
🦴 Anatomy & Pathophysiology
Parkinson's disease primarily affects the substantia nigra pars compacta (SNpc), a midbrain nucleus responsible for producing dopamine that projects to the striatum (caudate nucleus and putamen) via the nigrostriatal pathway. Loss of approximately 60–80% of SNpc dopaminergic neurons is required before clinical motor symptoms emerge, reflecting the brain's compensatory capacity.
Core Pathology
- Lewy bodies: Eosinophilic intracellular inclusions containing misfolded alpha-synuclein protein. Per the Parkinson's Foundation, these aggregates disrupt neuronal function and are the pathological hallmark of both PD and Dementia with Lewy Bodies (DLB).
- Braak staging: Alpha-synuclein pathology spreads in a predictable pattern (Braak stages 1–6), beginning in the olfactory bulb and dorsal motor nucleus (explaining anosmia and autonomic symptoms pre-dating motor features), ascending to substantia nigra (motor symptoms), and eventually involving the neocortex (dementia).
Basal Ganglia Circuit Disruption
Normal motor control requires a balance between the direct pathway (facilitating movement, dopamine D1 receptor-mediated) and the indirect pathway (suppressing unwanted movement, dopamine D2 receptor-mediated). Dopamine depletion increases inhibitory output from the globus pallidus internus (GPi) and subthalamic nucleus (STN) to the thalamus, reducing thalamo-cortical activation and producing bradykinesia and rigidity. Deep brain stimulation targets the STN or GPi to modulate this abnormal inhibitory output.
Parkinson-Plus Syndromes: Key Pathological Differences
- PSP (G23.1): Tau protein accumulation (tauopathy); affects the subthalamic nucleus, globus pallidus, superior colliculus; explains vertical gaze palsy
- MSA (G23.2/G23.3): Alpha-synuclein oligodendroglial inclusions (glial cytoplasmic inclusions); involves striatonigral system (MSA-P) and olivopontocerebellar system (MSA-C)
- DLB (G31.83): Widespread cortical Lewy body pathology; overlaps with PD but dementia onset precedes or coincides with motor features
💊 Medication Impact / Treatment
Dopaminergic Pharmacotherapy
Levodopa combined with carbidopa (the decarboxylase inhibitor) remains the most effective symptomatic treatment. Levodopa-carbidopa intestinal gel (Duopa, HCPCS J7340) is indicated for advanced PD with severe motor fluctuations via continuous jejunal infusion. Per FDA labeling, motor fluctuation documentation is essential to justify Duopa therapy.
| Drug Class | Examples | Coding/Documentation Impact |
|---|---|---|
| Levodopa/carbidopa (oral) | Sinemet, Rytary (extended release) | Wearing-off → G20.A2; dyskinesia → G20.B1/B2; document "with fluctuations" if applicable |
| Levodopa/carbidopa intestinal gel | Duopa (J7340) | Advanced PD indicator; requires gastrostomy; document severe motor fluctuations |
| Dopamine agonists | Pramipexole (Mirapex), ropinirole (Requip), rotigotine patch (Neupro) | Impulse control disorders as adverse effects — code separately if documented |
| MAO-B inhibitors | Selegiline, rasagiline (Azilect), safinamide (Xadago) | Drug interactions with opioids, antidepressants — document for MDM complexity |
| COMT inhibitors | Entacapone (Comtan), opicapone (Ongentys) | Used to extend levodopa effect; dyskinesia may increase — affects G20.B subcode |
| Amantadine (extended release) | Gocovri, Osmolex ER | Used specifically to reduce dyskinesia — presence confirms G20.B coding |
| Subcutaneous apomorphine | Apokyn (HCPCS J0364 — verify current J-code) | On-demand for "off" episodes; requires documented "off" episodes → G20.A2/G20.B2 |
| Anticholinergics | Trihexyphenidyl, benztropine | Used for tremor; cognitive side effects in elderly; contraindicated in PDD |
| Antipsychotics (PD-safe) | Quetiapine (low dose), pimavanserin (Nuplazid) | Pimavanserin specifically for PD psychosis — document hallucinations for medical necessity |
Wearing-off and dyskinesia in PD are disease progression phenomena, not adverse drug effects. Per Practical Neurology, coding these as T42.8X5 (adverse effect of antiparkinsonism drugs) is incorrect. "Off" episodes and levodopa-induced dyskinesia should be captured through the G20.A2, G20.B1, or G20.B2 subcodes based on clinical features, not adverse effect codes.
Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.
← Back to All Clinical Documentation Guides
🔒 Register or sign in to read the full guide
Unlock the full guide including:
- • 📘 ICD-10-CM Guidelines (FY2026)
- • 🔢 ICD-10-CM Code Set (FY2026)
- • 🔎 Indexing
- • 🏥 CPT (2026)
- • 🧾 HCPCS (2026)
- • 📚 AHA Coding Clinic (Recent Guidance)
- • 💰 HCC / Risk Adjustment (v28)
- • ✍️ CDI Query Templates
- • 🧑⚕️ Treatments (Clinical)
- • 🎓 Patient Education / Summary
